Pursuant to Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''SEBI Listing Regulations''), please find ....
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech has submitted its Annual Report for FY ended March 31, 2025, along with the Notice of the 32nd AGM scheduled for September 26, 2025 via video conference. The Board has recommended a 10% dividend (₹1 per share) with a record date of September 19, 2025. Standalone revenue declined 12.13% to ₹151.46 Crores and PAT fell 28.95% to ₹9.45 Crores, while consolidated revenue dropped 9.35% to ₹162.55 Crores and PAT declined 30.95% to ₹6.56 Crores, mainly because the oncology and domestic CVD (Medicamen Life Sciences) divisions are yet to break even. Key positives include receipt of first US FDA approval (Bortezomib Injection), EU-GMP certification for Bhiwadi facility, and three new CDMO contracts with US-based partners.
Shareholders will see lower earnings with a modest 10% dividend (same as last year). The stock may face pressure due to the steep fall in profits, though the new US FDA approval and CDMO contracts signal future growth potential as the company transitions from infrastructure build to commercial scale-up.